40.17
-0.09(-0.22%)
Currency In USD
| Previous Close | 40.26 |
| Open | 40.55 |
| Day High | 40.98 |
| Day Low | 40.14 |
| 52-Week High | 41.7 |
| 52-Week Low | 29.66 |
| Volume | 2.28M |
| Average Volume | 3.83M |
| Market Cap | 17.44B |
| PE | 22.95 |
| EPS | 1.75 |
| Moving Average 50 Days | 39.05 |
| Moving Average 200 Days | 35.89 |
| Change | -0.09 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $995.54 as of January 11, 2026 at a share price of $40.17. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 5 years ago, it would be worth $856.87 as of January 11, 2026 at a share price of $40.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
GlobeNewswire Inc.
Dec 29, 2025 9:40 PM GMT
Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portio
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
GlobeNewswire Inc.
Dec 16, 2025 12:15 PM GMT
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Nel
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
GlobeNewswire Inc.
Dec 04, 2025 12:10 PM GMT
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales